STOCK TITAN
  1. Home
  2. News
  3. ACAD

Acadia Pharmaceuticals Inc. - ACAD STOCK NEWS

Welcome to our dedicated page for Acadia Pharmaceuticals news (Ticker: ACAD), a resource for investors and traders seeking the latest updates and insights on Acadia Pharmaceuticals stock.

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders. Established with a commitment to scientific excellence and leadership in CNS research, Acadia's proprietary drug discovery platform has enabled the creation of a robust portfolio targeting conditions such as Parkinson's disease psychosis, Alzheimer's disease psychosis, Rett syndrome, and schizophrenia.

Acadia's pivotal achievements include the development and commercialization of NUPLAZID, the first and only FDA-approved treatment for hallucinations and delusions associated with Parkinson’s disease psychosis, and DAYBUE, the first and only FDA-approved drug for the treatment of Rett syndrome. The company's clinical-stage development efforts are focused on treating the negative symptoms of schizophrenia, Prader-Willi syndrome, Alzheimer's disease psychosis, and other neuropsychiatric symptoms in CNS disorders.

Situated in San Diego, one of the largest biotechnology hubs in the United States, Acadia benefits from proximity to over 400 companies and renowned research institutions like the Salk Institute for Biological Studies. This strategic location supports Acadia's mission to bring groundbreaking therapies to patients in need.

Financially, Acadia has shown significant growth, with total revenues reaching $205.8 million for the first quarter of 2024, reflecting a 74% year-over-year increase, largely due to the strong market performance of NUPLAZID and the addition of DAYBUE. The company continues to invest in its pipeline and commercial operations, maintaining a solid cash position with $470.5 million in cash, cash equivalents, and investment securities as of March 31, 2024.

Recent highlights include participation in major healthcare conferences, strategic appointments to enhance leadership in research and development, and ongoing efforts to expand the reach of DAYBUE beyond the U.S. market. Acadia’s unwavering dedication to advancing neuroscience and improving patient outcomes underscores its long-term growth potential and commitment to innovation in the biopharmaceutical landscape.

News

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary
Acadia Pharmaceuticals Inc. announces the granting of inducement awards to new employees in the form of stock options and restricted stock units. The awards are approved by the Compensation Committee and are in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price of $30.66 per share and will vest over four years, while the RSUs will also vest over four years. The awards are subject to the terms and conditions of Acadia’s 2023 Inducement Plan and an applicable award agreement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.72%
Tags
none
-
News

Acadia Announces the Passing of Former President Srdjan (Serge) Stankovic

Rhea-AI Summary
Acadia Pharmaceuticals Inc. announces the passing of its former President, Srdjan Stankovic M.D., M.S.P.H. Serge led Acadia's Research and Development organization for more than seven years, contributing to the approval and launch of NUPLAZID® for Parkinson's disease psychosis and DAYBUE™ for Rett syndrome. His passing is mourned by friends, colleagues, and the company. Serge's significant contributions to Acadia, patients, and caregivers are remembered and honored.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.09%
Tags
none
-
News

Acadia Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024

Rhea-AI Summary
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024, at 9:00 a.m. Pacific Time. A live webcast will be accessible on the company’s website, www.acadia.com, and an archived recording will be available for approximately one month following the presentation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.37%
Tags
conferences
News

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) granted inducement awards consisting of non-qualified stock options and restricted stock units to eight new employees under Acadia’s 2023 Inducement Plan. Each stock option has an exercise price per share equal to $28.47 per share and will vest over four years. The RSUs will also vest over four years. The awards are subject to the terms and conditions of Acadia’s 2023 Inducement Plan and the terms and conditions of an applicable award agreement covering the grant.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.82%
Tags
none
-
News

Delaware District Court Rules in Favor of Acadia on Formulation Patent Construction (Markman) Claims Regarding NUPLAZID® (pimavanserin)

Rhea-AI Summary
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) receives a favorable ruling from the U.S. District Court for the District of Delaware regarding its '721 formulation patent for NUPLAZID® (pimavanserin), the drug for the treatment of Parkinson's Disease Psychosis. The Court ruled in favor of Acadia on all disputed claim construction points, affirming the strength of the patent. This ruling cancels the claims construction hearing scheduled for December 19, 2023, and the case remains scheduled for trial in December 2024. Earlier in the day, the Court also granted summary judgment to Acadia, confirming validity of Acadia's '740 composition of matter patent. The formulation patent is set to expire in 2038, while the method of use patent on the 10mg tablet of NUPLAZID runs to 2037 and the NUPLAZID composition of matter patent runs to 2030.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.44%
Tags
none
-
News

Delaware Federal District Court Rules in Favor of Acadia Pharmaceuticals in NUPLAZID® (pimavanserin) Patent Litigation

Rhea-AI Summary
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) has won a summary judgment in the U.S. District Court for the District of Delaware, confirming the validity of the NUPLAZID® '740 composition of matter patent. The court ruled in favor of Acadia on all grounds, concluding the litigation against MSN Laboratories Pvt. Ltd., MSN Pharmaceuticals, Inc., and other ANDA filers. The '740 patent protects NUPLAZID into 2030, with additional patents safeguarding the drug until 2037 and 2038. This outcome demonstrates Acadia’s commitment to protecting its innovations in new treatments for disorders with high unmet need.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
34.48%
Tags
none
News

Acadia Pharmaceuticals Initiates Pivotal Phase 3 Study of Carbetocin (ACP-101) for the Treatment of Hyperphagia in Prader-Willi Syndrome

Rhea-AI Summary
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) has initiated the Phase 3 COMPASS PWS study to evaluate the efficacy and safety of carbetocin nasal spray (ACP-101) for the treatment of hyperphagia in Prader-Willi syndrome (PWS). PWS is a rare, neurobehavioral genetic disorder estimated to affect 8,000 to 10,000 patients in the United States. The Phase 3 trial will involve approximately 170 children and adults aged five to 30 years with PWS and will focus on reducing hyperphagia-related behaviors. There is currently no FDA-approved treatment for hyperphagia in PWS, presenting serious challenges for patients and their families. The primary efficacy endpoint of the study is the change in the hyperphagia questionnaire for clinical trials (HQ-CT) score from baseline to week 12.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.68%
Tags
clinical trial
-
News

Acadia Pharmaceuticals Initiates Phase 2 Clinical Trial of ACP-204 for the Treatment of Alzheimer’s Disease Psychosis

Rhea-AI Summary
Acadia Pharmaceuticals Inc. (ACAD) initiates Phase 2 study for ACP-204 in treating hallucinations and delusions associated with Alzheimer's disease psychosis (ADP). Approximately 30% of the 6.5 million people in the US with AD experience psychosis. The global, multi-center, randomized, double-blind, placebo-controlled trial will enroll approximately 318 patients and evaluate ACP-204 30 mg and 60 mg doses compared to placebo. The primary endpoint is change from Baseline in the Scale for the Assessment of Positive Symptoms–Hallucinations and Delusions subscales (SAPS-H+D) total score at Week 6. Planned Phase 3 studies will enroll approximately 378 patients with ADP, with an option for long-term open-label extension (OLE) study participation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.76%
Tags
clinical trial
-
News

Acadia Pharmaceuticals Announces Change in Research and Development Leadership

Rhea-AI Summary
Acadia Pharmaceuticals Inc. (ACAD) announces the departure of Dr. Doug Williamson, the Executive Vice President, Head of Research and Development, who will be leaving the company to pursue other opportunities. Dr. Williamson joined Acadia in January 2023 and will continue in his role during a transitional period. The company has initiated a search for his replacement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.05%
Tags
none
News

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced the grant of inducement awards to nine new employees, including non-qualified stock options to purchase 10,481 shares of common stock and 6,275 restricted stock units (RSUs). Each stock option has an exercise price of $24.07 per share and will vest over four years, while the RSUs will vest over four years as well. The awards are subject to the terms and conditions of Acadia’s 2023 Inducement Plan and an applicable award agreement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.72%
Tags
none

FAQ

What is the current stock price of Acadia Pharmaceuticals (ACAD)?

The current stock price of Acadia Pharmaceuticals (ACAD) is $16.87 as of December 20, 2024.

What is the market cap of Acadia Pharmaceuticals (ACAD)?

The market cap of Acadia Pharmaceuticals (ACAD) is approximately 2.8B.

What does Acadia Pharmaceuticals Inc. specialize in?

Acadia Pharmaceuticals Inc. specializes in developing and commercializing innovative medicines for central nervous system (CNS) disorders.

Where is Acadia Pharmaceuticals headquartered?

Acadia Pharmaceuticals is headquartered in San Diego, California.

What are some of Acadia's key products?

Key products include NUPLAZID, for hallucinations and delusions associated with Parkinson’s disease psychosis, and DAYBUE, for the treatment of Rett syndrome.

What recent financial performance did Acadia report?

For the first quarter of 2024, Acadia reported total revenues of $205.8 million, marking a 74% increase year over year.

What are Acadia's current research focuses?

Acadia's research focuses include the negative symptoms of schizophrenia, Prader-Willi syndrome, Alzheimer’s disease psychosis, and other neuropsychiatric symptoms in CNS disorders.

What recent achievements has Acadia Pharmaceuticals announced?

Recent achievements include strategic leadership appointments, participation in major healthcare conferences, and advancements in their clinical-stage development efforts.

How does Acadia support the Rett syndrome community?

Acadia supports the Rett syndrome community through initiatives like the Rett Sibling Scholarship program and creating awareness with projects like Magnolia’s Guide to Adventuring.

What is the significance of Acadia's location in San Diego?

San Diego is one of the largest biotechnology clusters in the U.S., providing Acadia access to a vibrant ecosystem of over 400 companies and prestigious research institutions.

How has Acadia's product portfolio grown recently?

Acadia's portfolio has grown with the addition of DAYBUE, enhancing their market presence and addressing unmet medical needs in CNS disorders.

What is Acadia’s approach to drug discovery?

Acadia’s proprietary drug discovery platform focuses on internal discoveries, innovative therapeutic approaches, and addressing large unmet needs in CNS disorders.

Stock ACAD logo
Acadia Pharmaceuticals Inc.

Nasdaq:ACAD

ACAD Rankings

#1708 Ranked by Market Cap
N/A Ranked by Dividends

ACAD Stock Data

2.80B
164.23M
0.55%
97.52%
6.16%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SAN DIEGO